sub:assertion {
  d:DB01608 v:identifier "DB01608" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB01608" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB01608> ;
    dv:drugbank-id "DB01608" ;
    dv:x-atc <http://bio2rdf.org/atc:N05AC01> ;
    dv:x-cas <http://bio2rdf.org/cas:2622-26-6> ;
    dv:x-chebi <http://bio2rdf.org/chebi:31981> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:4585> ;
    dv:x-dpd <http://bio2rdf.org/dpd:1926756> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D01485> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA164781043> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:4747> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46505085> ;
    dct:description "Propericiazine is a phenothiazine of the piperidine group. It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected. It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects and an action on the extrapyramidal system.  It is used as an adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness. Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade."@en ;
    dct:identifier "drugbank:DB01608" ;
    dct:title "Propericiazine"@en ;
    a dv:Drug ;
    rdfs:label "Propericiazine [drugbank:DB01608]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB01608> .
}